Imaging Impaired Endothelium in Atherothrombosis
to assess experimental atherosclerosis biology in vivo. We first assessed the cellular distribution of the fluorescent USPIO in rabbit atheroma and found that its cellular targeting profile appeared diffusion limited. This finding motivated us to investigate whether an impaired endothelial barrier function might govern CLIO-CyAm7 nanoparticle deposition into atheroma. Next, to understand the relationship between nanoparticle deposition and plaque thrombosis, we used a modified procedure developed by Constantinides to trigger thrombosis [5] [6] [7] to assess whether sites of mural thrombosis accumulated CLIO-CyAm7. Finally, we analyzed the ability of CLIO-CyAm7 nanoparticles to enable intravascular near-infrared fluorescence (NIRF) molecular imaging of impaired endothelial barrier function in vivo in coronary artery-sized vessels.
Methods
Materials and Methods are available in the online-only Data Supplement.
Animal Model of Atherothrombosis
Animal protocols were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care. New Zealand white rabbits (n=31) consumed a high-cholesterol diet for 2 weeks before abdominal aortic balloon injury followed by 6 weeks of 1% high-cholesterol diet and 4 weeks of normal chow ( Figure I in the Data Supplement). 5, 6 
CLIO-CyAm7 Studies of Rabbit Atherosclerosis and Triggered Atherothrombosis
Rabbits with atheroma underwent intravenous injection of NIRF USPIO nanoparticles (n=21, CLIO-CyAm7 group, Figure II in the Data Supplement) or saline (n=3) at the end of the preparation protocol. Rabbits were euthanized at 24 hours or underwent 2 rounds of thrombosis triggering 24 hours apart with Russell viper venom (0.15 mg/kg intraperitoneally; Sigma Chemical Co) followed 30 minutes later by histamine (0.02 mg/kg intravenously, Sigma Chemical Co). Rabbits underwent intravascular NIRF and ultrasound (IVUS) imaging during the double-triggering protocol ( Figure I in the Data Supplement). A subgroup of rabbits (n=7) also underwent assessment for impaired endothelial permeability assessed by Evans Blue dye leakage (6 mL intravenous injection 0.5%; Sigma Chemical Co) 30 minutes before euthanization. 8 A higher dose of CLIO-CyAm7 (5.0 mg/kg) was used in these rabbits to overcome partial fluorescence overlap with Evans Blue.
In Vivo Intra-Arterial NIRF Molecular Imaging and IVUS Structural Imaging

Intravascular 2-Dimensional NIRF Molecular Imaging
Before pharmacological triggering, 15 rabbits underwent in vivo intravascular NIRF imaging of CLIO-CyAm7 deposition using a custom-built standalone 2-dimensional (2D) NIRF catheter-based system (750 nm laser excitation). 9 Four 90 to 100 mm pullbacks from the iliac bifurcation to the renal arteries were performed through blood, without flushing. 9, 10 The peak target/background ratio was calculated for regions of atheroma across all pullbacks (MATLAB R2011a MathWorks). Regions with a luminal diameter of >5 mm were excluded because of NIR light attenuation.
IVUS Structural Assessment of Atherosclerosis and Atherothrombosis
IVUS images (Galaxy IVUS System, Boston Scientific) interrogated atheroma structure before triggering, and then after triggering to identify large luminal thrombi. IVUS images were coregistered to NIRF images using radiopaque markers on x-ray angiography. IVUS pre-and post-triggering images were coregistered to each other using side branches as fiducial markers.
Analysis of CLIO-CyAm7 Nanoparticle Distribution in Atheroma and Atherothrombosis
After euthanization, rabbits underwent fluorescence reflectance imaging, fluorescence microscopy, and histopathology analyses to determine the distribution of CLIO-CyAm7 nanoparticles in atheroma (NIH ImageJ). The percent positive CLIO-CyAm7 pixels were calculated in the superficial 100 μm of uniformly thresholded fluorescence microscopy images. In sections from rabbits injected with Evans Blue, the maximum distance from the luminal plaque surface to the deepest CLIO-CyAm7 signal, the Evans Blue signal, or internal elastic membrane (plaque thickness) were measured. Correlation coefficients were calculated to determine the relationship between these depths. See Data Supplement for details.
Statistical Analysis
For all analyses between 2 groups, nonparametric Mann-Whitney U test was used (GraphPad Prism v5.0, San Diego, CA). Thresholds for specificity and sensitivity calculations were determined using a receiver operator curve optimization. Data are presented as mean±SD or 95% confidence intervals.
Results
CLIO-CyAm7 Nanoparticles Localize to the Luminal Surface of Atheroma
Although USPIO nanoparticles are well-established cellular magnetic resonance imaging reporters for atherosclerosis, [11] [12] [13] their precise cellular and topographical distribution in coronary artery-sized atheroma is incompletely understood. NIRF nanoparticles allowed assessment of USPIO uptake in rabbit atheroma using fluorescence imaging (Figures 1 and 2 ). Ex vivo macroscopic and microscopic NIR fluorescence imaging illuminated plaque areas with high CLIO-CyAm7 uptake ( Figure 1A ). In contrast, minimal NIRF signal emerged in control rabbits receiving saline ( Figure 1B ), in accord with previous results. 9, [14] [15] [16] Aortic atheroma exhibited increased CLIO-CyAm7 nanoparticle signal compared with control areas ( Figure 1C , signal-to-noise ratio 18.1±11.3 versus 10.64±1.2 in the uninjured renal artery, P=0.03). On fluorescence microscopy, CLIO-CyAm7 primarily accumulated in the superficial intima, with a smaller component in deeper plaque regions ( Figures 1D, 1E , and 2). CLIO-CyAm7 deposition was not uniform circumferentially across the atheroma surface ( Figure 1D ). Fluorescence microscopic analysis of the superficial intima demonstrated increased CLIO-CyAm7+ deposition in atheroma compared with the uninjured aorta ( Figure 1F 
Cellular Distribution of Iron Oxide Nanoparticles in Atheroma
USPIO nanoparticles seem to localize primarily in macrophages in atheroma, 11, 17, 18 but detailed assessment of USPIO localization in other atheroma cells is limited. We, therefore, examined the cellular localization of CLIO-CyAm7 within plaque macrophages ( Figure 2A2 ), smooth muscle cells (SMCs; Figure 2A3 ), and endothelial cells ( Figure 2A1 ) and found evidence of CLIO-CyAm7 deposition within each of these 3 cell types (Figure 2) . Analysis of representative sections from each triggered rabbit demonstrated restriction of the CLIO-CyAm7 signal to the luminal plaque surface in the majority of rabbits (67%), despite the presence of numerous cells deeper within the atheroma (Figure 2A ). This observation suggested that restricted diffusion could also govern nanoparticle deposition.
The remaining 33% of rabbits showed evidence of deeper CLIO-CyAm7 deposition at the intimal-medial border ( Figure 2B ). CD31 staining for endothelial cells showed evidence of neovascularization in these deeper regions, providing a plausible access route for nanoparticles to deposit more deeply into atheroma. Although CLIO-CyAm7 localized near the CD31+ neovasculature ( Figure 2B1 ), CLIOCyAm7 signal did not localize to CD31+ cells, but rather targeted nearby macrophages identified by RAM11 staining ( Figure 2B2 ).
CLIO-CyAm7 Deposits in Areas of Impaired Endothelial Permeability
Evidence of heterogeneous CLIO-CyAm7 distribution across the atheroma surface ( Figure 1D ) and within areas of neovascularization ( Figure 2B ) indicated that CLIO-CyAm7 deposition could relate to regional alterations in endothelial permeability. We, therefore, tested this hypothesis by coinjecting Evans Blue, a fluorescent azo dye that binds albumin. Evans blue deposition in the intima indicates increased, abnormal endothelial permeability. 16, 19 After coinjection of Evans Blue in rabbits injected with CLIO-CyAm7, atheroma exhibited varying degrees of Evans Blue uptake ( Figure 3 ). The depth of Evans Blue fluorescence signal in plaques correlated well with the depth of CLIO-CyAm7 penetration (r=0.64, P=0.003, Figure 3E ). The depth of Evans blue penetration, Figure 3D and 3F).
In Vivo NIRF Molecular Imaging of CLIO-CyAm7 Deposition
In vivo detection of CLIO-CyAm7 nanoparticle deposition in atheroma could offer an approach to detect biologically high-risk plaques. Further experiments, therefore, investigated whether CLIO-CyAm7 could provide sufficient signal to enable intravascular NIRF imaging of atheroma in vivo. Intravascular NIRF imaging is a high-resolution approach emerging for molecular imaging of coronary artery-sized vessels. [20] [21] [22] Multimodality imaging, including x-ray angiography, 2D NIRF, and IVUS imaging, was performed before triggering ( Figure 4A through 4C, n=15 rabbits). Intravascular NIRF imaging performed through blood 9 demonstrated the ability to detect NIRF nanoparticle signal in areas of IVUS-confirmed atheroma ( Figure 4B and 4C) .
After pharmacological triggering with Russell viper venom and histamine to induce atherothrombosis, follow-up IVUS imaging at 48 hours revealed new luminal thrombi overlying areas of atheroma ( Figure 4C and 4D) . The average luminal diameter as measured by IVUS was 3.41±0.78 mm (range 1.93-5.87 mm), with some animals developing aneurysms ( Figure 4G ). Of note, multiple segments were larger than the typical 2.5 to 3.5 mm diameter of human coronary arteries to which the intravascular NIRF system is optimally calibrated. 9 Ex vivo fluorescence reflectance imaging at 72 hours after initial CLIO-CyAm7 injection still detected CLIO-CyAm7 in atheroma ( Figure 4F ). Atheroma generated a significantly higher peak target/background ratio compared with the uninjured control aorta (peak target/background ratio 2.86±1.82 versus 1.55±0.65, P=0.001, respectively, Figure 4H ; Figure III in the Data Supplement).
CLIO-CyAm7 Nanoparticle Deposition Underlies Areas of Plaque Thrombosis In Vivo and by Histological Analysis
Ten of 15 rabbits (67%) undergoing pharmacological triggering developed plaque thrombosis as confirmed by histological examination ( Figure 5) . A total of 21 of 51 atheroma segments compiled from all rabbits exhibited adherent thrombus (41%) on Carstairs' staining. In vivo IVUS images demonstrated thrombus in 4 of 9 rabbits with confirmation on Carstairs' stain after euthanization. IVUS-detectable thrombi were larger than those identified by Carstairs' alone (4.4±5.0 μm 2 versus 0.42±0.39 μm 2 ), suggesting that IVUS had lower sensitivity to detect smaller thrombi.
Quantitative analysis revealed that the 21 plaques with adherent Carstairs'-positive thrombus exhibited higher CLIOCyAm7 accumulation than the 30 plaques without thrombus ( Figure 5C , 2.1±1.7% versus 1.5±1.9%, respectively, P=0.045). CLIO-CyAm7 nanoparticles abutted thrombi, particularly at plaque shoulders ( Figure 5D and 5G). Receiver This threshold provided a sensitivity and specificity of 82.6% (confidence intervals, 61.2%-95%) and 61.8% (confidence intervals, 43.6%-77.8%), respectively, for plaque thrombosis. Using this threshold criterion, the positive predictive value of a CLIO-positive plaque for plaque thrombosis was 59.4% (confidence intervals, 40.6%-76.3%) and the negative predictive value was 84.0% (confidence intervals, 63.9%-95.4%).
Discussion
Atherosclerosis progression and plaque destabilization involves the interplay between multiple cell types, including A subgroup of rabbits injected with CLIO-CyAm7 also received Evans Blue shortly before euthanization. A, Atheroma with extensive Evans blue uptake (yellow) throughout the intima limited peripherally by the internal elastic membrane (autofluorescence, AF, blue). CLIO-CyAm7 (red) similarly penetrates below the endothelial layer throughout the intima. B, Atheroma with minimal, superficial Evans blue uptake and minimal CLIO-CyAm7 signal. C, Evans Blue and CLIO-CyAm7 depths of penetration correlated strongly (r=0.64, P=0.003, n=19). D, Weak correlation between the depth of Evans Blue penetration and plaque thickness (r=0.14, P=0.61, n=19). Scale bar, 100 μm. H&E indicates hematoxylin and eosin. Imaging Impaired Endothelium in Atherothrombosis 55±0.65, P=0.001) . Imaging Impaired Endothelium in Atherothrombosis macrophages, endothelial cells, and SMCs. This study investigated the role of impaired endothelial permeability and atheroma cell distribution by assessing the distribution of NIRF CLIO-CyAm7 nanoparticles 12, 17 in experimental atherothrombosis. The overall results demonstrate that plaques that exhibit impaired endothelial permeability and surface atheroma cellularity have heightened susceptibility to subsequent thrombosis. From an imaging standpoint, the current data sharpen the understanding of nanoparticle targeting in atheroma. USPIO nanoparticles can deposit in all major atheroma cell types and specifically in areas of impaired endothelial permeability, as supported by Evans Blue deposition and neovessel presence. In addition, CLIO-CyAm7 enables intravascular NIRF imaging of various atheroma cell types and altered endothelial permeability in vivo through blood, offering the potential for translational detection of biologically high-risk plaques.
Despite evaluation of USPIO in several experimental and clinical atherosclerosis studies, the precise targeting profile of USPIO nanoparticles in atherosclerosis is incompletely understood. The current investigation leveraged the engineered fluorescence capabilities of the CLIO-CyAm7 USPIO nanoparticle and examined over 50 plaques in the rabbit aorta, a vessel of similar caliber as human coronary arteries. Although USPIOs are established macrophage reporter agents, nonmacrophage cells might also contribute to USPIO retention in atherosclerosis. 19, [23] [24] [25] This study confirmed that USPIOs could not only target plaque macrophages but also target some periluminal plaque SMCs and intimal endothelial cells. SMCs undergo phenotypic changes in the inflammatory milieu of the atherosclerotic plaque. [26] [27] [28] Lesional SMCs bear adhesion molecules, class II major histocompatibility molecules, and tissue factor, indicating inflammatory activation and the potential to drive atherothrombosis. 26, [28] [29] [30] [31] [32] [33] Inflammatory SMCs can, thus, phagocytose CLIO-CyAm7 given its similar size compared with low density lipoprotein. 25, 34 In this regard, the nanoparticle preparation ferumoxtran, a clinical analog of CLIO, can localize within cells with both SMC-and macrophage-like characteristics on electron microscopy. 17, 24 The overall findings extend previous work by showing that USPIO nanoparticles accumulate in macrophages, pathological endothelial cells, and inflammatory SMCs. 19, 24, [34] [35] [36] This study demonstrated that USPIO nanoparticle deposition was heterogeneous, even across a plaque's circumference ( Figure 1D ). Histological analyses revealed that CLIO-CyAm7 deposited primarily within the first 100 μm of the plaque surface, despite abundant plaque cells, including macrophages, throughout deeper regions of the plaques. The heterogeneous distribution of CLIO nanoparticles in atheroma suggested that altered endothelial permeability in atherosclerosis could modulate nanoparticle deposition, a phenomenon identified in cancer studies as the enhanced permeability and retention effect. 37 This hypothesis was confirmed when Evans blue deposition identified impaired endothelial permeability consistently in areas of CLIO-CyAm7 deposition. The depth of Evans Blue stain further correlated with the depth of CLIO-CyAm7 penetration, indicating that enhanced plaque permeability tracked with impaired endothelial permeability (Figure 3 ). 
Imaging Impaired Endothelium in Atherothrombosis
These results provide evidence that impaired endothelial barrier function, often but variably present in atherosclerosis, links to USPIO deposition in atheroma. These findings parallel those in arteriovenous fistulae that also exhibit pathological endothelial permeability 19 and is further supported by CLIOCyAm7 accumulation in deeper plaque macrophages adjacent to areas of microvascular CD31+ endothelial cells ( Figure 2B) . Neovascularization, the growth of the vasa vasorum from the adventitia to the media and eventually in the deep intima, promotes intraplaque hemorrhage due to the fragile, leaky neovessels, and increases the risk of plaque rupture. 38 Thus, USPIO nanoparticle localization in the atheroma intima and regions of neovascularization illuminates impaired endothelial barrier function in atherosclerosis. This capability might also have future application to assess superficial plaque erosion, a mechanism of coronary thrombosis of increasing interest in the current era. 3 Attesting to the important pathological consequences of impaired endothelial barrier function and atheroma proinflammatory cells, plaques that developed triggered thrombosis showed enhanced USPIO nanoparticle uptake ( Figure 5H ). Nanoparticle deposition further occurred at plaque shoulders, areas associated with plaque disruption, and subsequent thrombosis. These findings suggest that USPIO nanoparticles distinguish specific atheroma and even regions of atheroma prone to develop thrombosis, and imaging of USPIO deposition might prove useful in enhancing subject-specific and plaque-specific risk of atherothrombotic events.
Alternative approaches to detect impaired endothelial permeability include dynamic contrast-enhanced magnetic resonance imaging using albumin-binding contrast agents 6, 8, 39, 40 or indocyanine green-based NIRF imaging. 15, 16 Comparatively, CLIO-CyAm7 may provide more durable cellular uptake, including into macrophages, endothelial cells, and SMCs, and therefore can also serve as a reporter of cellular inflammation. Compared with magnetic resonance imaging approaches, which have enabled clinical molecular magnetic resonance imaging of inflamed carotid plaques, 12, 17 higher resolution imaging approaches appear necessary for coronary artery imaging. [20] [21] [22] In a translational substudy, we leveraged the NIRF capabilities of the CLIO-CyAm7 USPIO to perform intravascular NIRF imaging, a clinically emerging approach for highresolution imaging of human coronary arteries. [20] [21] [22] [41] [42] [43] In vivo NIRF imaging of CLIO-CyAm7 deposition in coronary-sized vessels demonstrated significantly higher NIRF signal in rabbit aortic plaques than in control areas. The results demonstrate a new capability of NIRF imaging to assess atheroma cellularity and because of impaired endothelial barrier function in vivo. The current intravascular NIRF imaging results have promising clinical applicability, as NIR fluorophores, 15, 44 USPIOs, 12, 17 and intracoronary NIRF imaging 42 are clinically translatable. This study has certain limitations. Although triggering often provoked the formation of adherent thrombi, these sites rarely displayed plaque rupture characterized by a disrupted fibrous cap, a potential difference with human atherothrombosis, although plaque rupture has been previously described after this pharmacological triggering procedure. [45] [46] [47] However, this finding of mural thrombosis at sites of defective endothelial barrier function enhances the relevance of the present findings to superficial erosion, an increasingly recognized cause of acute coronary syndrome. These results further agree with the findings on thrombosed lesions observed in myocardial infarction-prone atherosclerotic rabbits treated with a spasmogenic triggering regimen. 48 Higher-resolution confocal microscopic colocalization of CLIO-CyAm7 nanoparticles with cell-specific fluorescence antibodies was not possible, as commercial confocal systems are not equipped with 750 nm range lasers; we therefore used epifluorescence colocalization approaches. Finally, in vivo fluorescence reflectance imaging is limited in a distance-dependent manner as described previously, resulting in semiquantitative NIRF signal assessment. 9 NIRF imaging has limited depth sensing, and therefore atheroma within aneurysmal segments (eg, 5.0 mm diameter, larger than a typical coronary artery) did not produce detectable in vivo NIRF signal. Since completion of this study, a combined optical coherence tomography-NIRF catheter became available for integrated molecular-structural imaging 49 ; however, optical coherence tomography signal detection requires saline-flushing, unlike the current standalone NIRF approach performed through flowing blood, without flushing.
In conclusion, this study demonstrates that USPIO nanoparticles deposit in plaque macrophages, SMCs and endothelial cells associated with zones of impaired surface endothelial permeability as well as zones of neovascularization. Nanoparticle deposition further occurs in plaques that progress to thrombosis. These results shed new mechanistic light into the pathophysiology of the thrombotic complications of atherosclerosis. Furthermore, intravascular imaging of NIRF nanoparticles may provide a novel translational approach to detect biologically high-risk plaques in vivo.
